Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLBCL Response Prediction Model Pilot
NCT02405078Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2015
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response to therapy at 42 days. Started Oct 2015; status: completed.
Beyond the preview
Go deeper on NCT02405078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405078.